<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221101056358N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-11-21</date_registration>
      <primary_sponsor>Semnan University of Medical Sciences</primary_sponsor>
      <public_title>The Evaluation of adding tecar therapy effect on routine physiotherapy treatments compared to placebo tecar and routine physiotherapy treatments on pain, disability and electrical activity of erector spine muscles in patients with non-specific chronic low back pain</public_title>
      <acronym></acronym>
      <scientific_title>The Evaluation of adding tecar therapy effect on routine physiotherapy treatments compared to placebo tecar and routine physiotherapy treatments on pain, disability and electrical activity of erector spine muscles in patients with non-specific chronic low back pain</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>32</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66611</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: The sampling method in this research is done in the form of simple sampling. Allocation of samples (into two groups) is done randomly using the Stratified Permuted Block Randomization method with 5 blocks of 4 and 8 assigned to two groups
 1                         BBBAABAA

2                      ABAB

3                     AABBAABB

4                    AABBBABA

5                     AABB.            
 Considering A as the routine physiotherapy treatment group and B as the exercise group, the methodologist randomly selects a number between 1 and 5 after each patient enters. The result of the lottery result of the corresponding block number is determined. In the next step, by referring to the above table, the type of intervention (whether it is A or B) is determined. For example, let's assume that the number 3 appears at some point in the lottery, by referring to block three, we can see that before AAB choices were made and now it is the turn to perform intervention B, then, the expert is asked for this patient exercise and Takar should be done together. In the image that the block number appeared in the lottery that all the previous options were completed, the lottery is completed again until the number of duplicate samples is completed, Blinding description: The main researcher will not divide the samples into two groups, and this work will be done by the research assistant who is a physiotherapy expert, and the information obtained from the data will be provided to the statistical evaluator in a coded and non-recognizable form. And the evaluator will not know about the grouping of people. Also, the intervention is done by another person, and the evaluation before and after the treatment is done by the main researcher, so this study is a thriple-blind one.</study_design>
      <phase>N/A</phase>
      <hc_freetext>non-specific chronic low back pain.</hc_freetext>
      <i_freetext>Intervention 1: The patients in the treatment group are treated for 5 sessions a week and a total of 10 sessions. 10 minutes of capacitive Tecar and 10 minutes of resistance Tecar are used. The frequency of the capacitive phase of the treatment is 600 KHZ and the frequency of the resistive phase of the treatment is 450 KHZ. Intensity in both types of treatment is 10-12 w or 0.42 j/cm2 for an area of ​​228.2 cm. The routine physiotherapy treatment is 10 sessions of TENS along with therapeutic exercises similar to the sessions of the treatment group and in each treatment session for 35 minutes (20 minutes Low-frequency TENS, with a frequency of 5 Hz and a pulse duration of 300 microseconds and the use of IR for 15 minutes on the lower back area), therapeutic exercise including lumbar pelvic stabilization exercises and paraspinal stretching. Intervention 2: Control group: Routine physiotherapy treatment, 10 sessions of TENS along with therapeutic exercises similar to the sessions of the treatment group and in each treatment session for 35 minutes (20 minutes of low frequency TENS, with a frequency of 5 Hz and pulse duration of 300 microseconds and use of IR for 15 minutes on the lower back area), therapeutic exercises include lumbar pelvic stabilization exercises and paraspinal stretching. Also, Tecar placebo is used.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is uncertain variables that are included in intervention</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Morteza Heydari Nasir</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>East Sahib Al Zaman St. corner of Pakan Alley</address>
        <city>Asadabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6541833586</zip>
        <telephone>+98 81 3311 7923</telephone>
        <email>m.heydarinasir@gmail.com</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Morteza Heydari Nasir</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>East Sahib Al Zaman St. corner of Pakan Alley</address>
        <city>Asadabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6541833586</zip>
        <telephone>+98 81 3311 7923</telephone>
        <email>m.heydarinasir@gmail.com</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with symptoms of chronic back pain who are between 20 and 60 years old
Diagnosis of chronic back pain for at least 12 weeks
Visual pain index 4-7
Patients with back pain who have no documentation of discopathy or disc herniation</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Contraindication of tecar therapy: neoplasm, regional infection, patients with cardiac pacemaker and pregnancy.
Active vertebral fracture
previous spine surgery
Rheumatoid diseases such as rheumatoid arthritis
infectious diseases
Systemic diseases that affect pain perception, such as diabetes and...
Local injection such as (local anesthesia, corticosteroid...)
Taking medicines and doing physiotherapy in the last 4 weeks</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M95-M99</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other disorders of the musculoskeletal system and connective tissue</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The patients in the treatment group are treated for 5 sessions a week and a total of 10 sessions. 10 minutes of capacitive Tecar and 10 minutes of resistance Tecar are used. The frequency of the capacitive phase of the treatment is 600 KHZ and the frequency of the resistive phase of the treatment is 450 KHZ. Intensity in both types of treatment is 10-12 w or 0.42 j/cm2 for an area of ​​228.2 cm. The routine physiotherapy treatment is 10 sessions of TENS along with therapeutic exercises similar to the sessions of the treatment group and in each treatment session for 35 minutes (20 minutes Low-frequency TENS, with a frequency of 5 Hz and a pulse duration of 300 microseconds and the use of IR for 15 minutes on the lower back area), therapeutic exercise including lumbar pelvic stabilization exercises and paraspinal stretching</i_keyword>
      <i_keyword>Control group: Routine physiotherapy treatment, 10 sessions of TENS along with therapeutic exercises similar to the sessions of the treatment group and in each treatment session for 35 minutes (20 minutes of low frequency TENS, with a frequency of 5 Hz and pulse duration of 300 microseconds and use of IR for 15 minutes on the lower back area), therapeutic exercises include lumbar pelvic stabilization exercises and paraspinal stretching. Also, Tecar placebo is used.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: Before the intervention and two weeks after the intervention and 1 month after the end of the last session of the intervention. Method of measurement: visual analogue scale- -.</prim_outcome>
      <prim_outcome>Functional disability. Timepoint: Before the intervention and two weeks after the intervention and 1 month after the end of the last session of the intervention. Method of measurement: Oswestry disability scale.</prim_outcome>
      <prim_outcome>Electrical activity of erector spine muscles. Timepoint: Before the intervention and two weeks after the intervention and 1 month after the end of the last session of the intervention. Method of measurement: Electromyographic device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Semnan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-10-31</approval_date>
        <contact_name>Ethics committee of Semnan University of Medical Sciences</contact_name>
        <contact_address>East Sahib Al Zaman Street, corner of Pakan Alley, P7 asadabad Hamadan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
